BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33419682)

  • 1. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
    Deek MP; Van der Eecken K; Phillips R; Parikh NR; Isaacsson Velho P; Lotan TL; Kishan AU; Maurer T; ; Boutros PC; Hovens C; Abramowtiz M; Pollack A; Desai N; Stish B; Feng FY; Eisenberger M; Carducci M; Pienta KJ; Markowski M; Paller CJ; Antonarakis ES; Berlin A; Ost P; Tran PT
    Eur Urol; 2021 Nov; 80(5):632-640. PubMed ID: 33419682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
    Hoang T; Sutera P; Nguyen T; Chang J; Jagtap S; Song Y; Shetty AC; Chowdhury DD; Chan A; Carrieri FA; Hathout L; Ennis R; Jabbour SK; Parikh R; Molitoris J; Song DY; DeWeese T; Marchionni L; Ren L; Sawant A; Simone N; Lafargue A; Van Der Eecken K; Bunz F; Ost P; Tran PT; Deek MP
    Prostate; 2024 Jan; 84(1):87-99. PubMed ID: 37812042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.
    Sutera P; Van Der Eecken K; Kishan AU; Hamid A; Grist E; Attard G; Lotan T; Mendes AA; Paller CJ; Carducci MA; Ross A; Wang H; Pienta K; Feng FY; Antonarakis ES; Ost P; Song DY; Greco S; Deville C; DeWeese T; Tran PT; Deek MP
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):713-719. PubMed ID: 35013522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
    Sutera P; Song Y; Shetty AC; English K; Van der Eecken K; Guler OC; Wang J; Cao Y; Bazyar S; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Kiess A; Song DY; DeWeese T; Pienta KJ; Barbieri C; Marchionni L; Ren L; Sawant A; Simone N; Berlin A; Onal C; Tran PT; Ost P; Deek MP
    Eur Urol Oncol; 2024 Jun; ():. PubMed ID: 38862340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
    Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
    Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer.
    Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
    Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
    Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.
    Swami U; Isaacsson Velho P; Nussenzveig R; Chipman J; Sacristan Santos V; Erickson S; Dharmaraj D; Alva AS; Vaishampayan UN; Esther J; Hahn AW; Maughan BL; Antonarakis ES; Agarwal N
    Eur Urol; 2020 Nov; 78(5):652-656. PubMed ID: 32624276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.
    Sutera P; Shetty AC; Song Y; Hodges T; Hoang T; Rana Z; Pienta K; Feng F; Song DY; DeWeese T; Gillessen S; Sweeney C; James N; Attard G; Deek M; Tran PT
    Eur Urol Oncol; 2024 Apr; 7(2):241-247. PubMed ID: 37558543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
    Cussenot O; Timms KM; Perrot E; Blanchet P; Brureau L; Solimeno C; Fromont G; Comperat E; Cancel-Tassin G
    Eur Urol Oncol; 2024 Jun; 7(3):597-604. PubMed ID: 38182487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform.
    Lin E; Hahn AW; Nussenzveig RH; Wesolowski S; Sayegh N; Maughan BL; McFarland T; Rathi N; Sirohi D; Sonpavde G; Swami U; Kohli M; Rich T; Sartor O; Yandell M; Agarwal N
    Oncologist; 2021 Sep; 26(9):751-760. PubMed ID: 34157173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer.
    Hiew K; Hart CA; Ali A; Elliott T; Ramani V; Sangar V; Lau M; Maddineni S; Brown M; Clarke N
    Eur Urol Focus; 2019 Sep; 5(5):831-841. PubMed ID: 29699892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.
    Deek MP; Taparra K; Phillips R; Velho PI; Gao RW; Deville C; Song DY; Greco S; Carducci M; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Tran PT; Stish BJ
    Eur Urol Oncol; 2021 Jun; 4(3):447-455. PubMed ID: 32536574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.
    Sutera P; Deek MP; Van der Eecken K; Shetty AC; Chang JH; Hodges T; Song Y; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Ross A; Schaeffer E; Roberts N; Song DY; DeWeese T; Pienta KJ; Antonarakis ES; Ost P; Tran PT
    Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1095-1101. PubMed ID: 36708787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
    Sutera P; Song Y; Van der Eecken K; Shetty AC; English K; Hodges T; Chang J; Fonteyne V; Rana Z; Ren L; Mendes AA; Lumen N; Delrue L; Verbeke S; De Man K; Song DY; Pienta K; Feng FY; Joniau S; Lotan T; Lane B; Kiess A; Rowe S; Pomper M; DeWeese T; Deek M; Sweeney C; Ost P; Tran PT
    Eur Urol; 2023 Dec; 84(6):531-535. PubMed ID: 37173210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
    Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
    Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.